The House of MedTech

This program is fundamentally a CE Mark clinical and market access program and investment is a secondary objective. ​Fund-raising is also a long process and could happen months after the program ends. Therefore, we provide opportunities for our startups to connect and network with key stakeholders in the venture capital industry through our R3i Deal Desk. Each opportunity is a chance to start building a longer-term relationship with potential investors, and to explore non dilutive funding pathways via the European grant options.